Latest Insider Transactions at Nuance Communications, Inc. (NUAN)
This section provides a real-time view of insider transactions for Nuance Communications, Inc. (NUAN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuance Communications, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuance Communications, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2022
|
Lloyd Carney Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,519
-100.0%
|
-
|
|
Mar 04
2022
|
Mark D Benjamin Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,209,427
-100.0%
|
-
|
|
Mar 04
2022
|
Mark D Benjamin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
906,000
+50.0%
|
-
|
|
Mar 04
2022
|
Robert Weideman EVP & GM, Enterprise Division |
SELL
Sale (or disposition) back to the issuer
|
Direct |
325,225
-99.76%
|
-
|
|
Mar 04
2022
|
Robert Weideman EVP & GM, Enterprise Division |
BUY
Grant, award, or other acquisition
|
Direct |
227,534
+50.0%
|
-
|
|
Mar 04
2022
|
Wendy Cassity EVP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
239,329
-78.69%
|
-
|
|
Mar 04
2022
|
Wendy Cassity EVP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
105,489
+50.0%
|
-
|
|
Mar 04
2022
|
Joseph Carl Petro EVP & Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
348,317
-97.38%
|
-
|
|
Mar 04
2022
|
Joseph Carl Petro EVP & Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
228,669
+50.0%
|
-
|
|
Mar 04
2022
|
Robert J Finocchio Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
131,167
-51.72%
|
-
|
|
Mar 04
2022
|
Thomas D Ebling Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,011
-53.89%
|
-
|
|
Mar 04
2022
|
Diana L Nole EVP & GM, Healthcare Division |
SELL
Sale (or disposition) back to the issuer
|
Direct |
175,797
-100.0%
|
-
|
|
Mar 04
2022
|
Diana L Nole EVP & GM, Healthcare Division |
BUY
Grant, award, or other acquisition
|
Direct |
56,461
+50.0%
|
-
|
|
Mar 04
2022
|
Mark R Laret Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
85,667
-52.64%
|
-
|
|
Mar 04
2022
|
Daniel J. Brennan Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,011
-53.89%
|
-
|
|
Mar 04
2022
|
Laura S. Kaiser Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
74,356
-53.04%
|
-
|
|
Mar 04
2022
|
Daniel David Tempesta EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
360,767
-98.85%
|
-
|
|
Mar 04
2022
|
Daniel David Tempesta EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,287
+50.0%
|
-
|
|
Mar 04
2022
|
Michal Katz Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
58,011
-53.89%
|
-
|
|
Mar 04
2022
|
Sanjay Vaswani Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,174
-60.67%
|
-
|
|
Mar 04
2022
|
Arthur G. Giterman Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
179,668
-73.32%
|
-
|
|
Mar 04
2022
|
Arthur G. Giterman Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,951
+50.0%
|
-
|
|
Mar 04
2022
|
Robert Dahdah EVP & Chief Revenue Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
391,249
-82.19%
|
-
|
|
Mar 04
2022
|
Robert Dahdah EVP & Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
196,505
+50.0%
|
-
|
|
Jan 04
2022
|
Lloyd Carney Director |
SELL
Open market or private sale
|
Direct |
5,670
-55.65%
|
$311,850
$55.29 P/Share
|
|
Jan 01
2022
|
Daniel J. Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+7.23%
|
-
|
|
Jan 01
2022
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+30.72%
|
-
|
|
Jan 01
2022
|
Robert J Finocchio Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+3.33%
|
-
|
|
Jan 01
2022
|
Mark R Laret Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+5.01%
|
-
|
|
Jan 01
2022
|
Sanjay Vaswani Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+17.59%
|
-
|
|
Jan 01
2022
|
Thomas D Ebling Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+7.23%
|
-
|
|
Jan 01
2022
|
Laura S. Kaiser Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+5.73%
|
-
|
|
Jan 01
2022
|
Michal Katz Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,519
+7.23%
|
-
|
|
Dec 21
2021
|
Robert Dahdah EVP & Chief Revenue Officer |
SELL
Bona fide gift
|
Direct |
1,000
-0.51%
|
$55,000
$55.2 P/Share
|
|
Dec 15
2021
|
Robert Dahdah EVP & Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
64,280
-24.72%
|
$3,535,400
$55.03 P/Share
|
|
Dec 09
2021
|
Mark D Benjamin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
72,501
-19.29%
|
$3,915,054
$54.86 P/Share
|
|
Dec 08
2021
|
Mark D Benjamin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
328,187
-46.61%
|
$17,722,098
$54.86 P/Share
|
|
Dec 08
2021
|
Diana L Nole EVP & GM, Healthcare Division |
SELL
Open market or private sale
|
Direct |
3,665
-1.5%
|
$197,910
$54.87 P/Share
|
|
Dec 07
2021
|
Robert Weideman EVP & GM, Enterprise Division |
SELL
Open market or private sale
|
Direct |
100,317
-50.66%
|
$5,417,118
$54.69 P/Share
|
|
Dec 06
2021
|
Mark D Benjamin Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
492,709
-41.17%
|
$27,098,995
$55.03 P/Share
|
|
Dec 03
2021
|
Mark D Benjamin Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,632
-0.8%
|
$529,760
$55.07 P/Share
|
|
Dec 03
2021
|
Wendy Cassity EVP & Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,752
-2.01%
|
$151,360
$55.07 P/Share
|
|
Dec 03
2021
|
Robert Dahdah EVP & Chief Revenue Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,088
-1.17%
|
$169,840
$55.07 P/Share
|
|
Dec 03
2021
|
Arthur G. Giterman Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,452
-1.16%
|
$79,860
$55.07 P/Share
|
|
Dec 03
2021
|
Diana L Nole EVP & GM, Healthcare Division |
SELL
Payment of exercise price or tax liability
|
Direct |
4,154
-3.27%
|
$228,470
$55.07 P/Share
|
|
Dec 03
2021
|
Joseph Carl Petro EVP & Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,820
-2.3%
|
$155,100
$55.07 P/Share
|
|
Dec 03
2021
|
Daniel David Tempesta EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,028
-2.67%
|
$166,540
$55.07 P/Share
|
|
Dec 03
2021
|
Robert Weideman EVP & GM, Enterprise Division |
SELL
Open market or private sale
|
Direct |
10,544
-5.06%
|
$579,920
$55.2 P/Share
|
|
Dec 03
2021
|
Robert Weideman EVP & GM, Enterprise Division |
SELL
Payment of exercise price or tax liability
|
Direct |
2,720
-1.29%
|
$149,600
$55.07 P/Share
|
|
Nov 30
2021
|
Robert Weideman EVP & GM, Enterprise Division |
SELL
Open market or private sale
|
Direct |
139,988
-39.85%
|
$7,699,340
$55.4 P/Share
|